Acrivon CEO to Discuss Pipeline Progress at TD Cowen Health Care Conference
Event summary
- Acrivon Therapeutics CEO Peter Blume-Jensen to participate in fireside chat on March 2, 2026 at TD Cowen Health Care Conference.
- Company advancing lead program ACR-368 in Phase 2 trial for endometrial cancer with FDA Fast Track and Breakthrough Device designations.
- ACR-2316 Phase 1 trial showing initial clinical activity in endometrial cancer, SCLC, and sqNSCLC.
- Acrivon developing ACR-6840, a CDK11-targeting development candidate.
The big picture
Acrivon's participation in the TD Cowen conference comes as the company seeks to validate its proprietary Generative Phosphoproteomics AP3 platform through clinical progress. The biotech is positioning itself as a leader in precision medicine, with multiple programs targeting underserved cancer indications. The strategic focus on pathway-specific inhibitors differentiates Acrivon in a competitive oncology landscape, though execution risks remain as it transitions from early to mid-stage development.
What we're watching
- Clinical Validation
- Whether ACR-368 can maintain its Fast Track designation momentum through Phase 2 trial results.
- Pipeline Diversification
- The pace at which Acrivon can advance its co-crystallography-driven pipeline programs into later-stage trials.
- Regulatory Strategy
- How Acrivon leverages its Breakthrough Device designation to accelerate commercialization of its OncoSignature assay.
Related topics